A "PET" area of interest: myocardial metabolism in human systolic heart failure

被引:26
作者
Kadkhodayan, Ana [1 ]
Coggan, Andrew R. [2 ]
Peterson, Linda R. [3 ]
机构
[1] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Dept Med, Div Cardiovasc, St Louis, MO 63110 USA
关键词
Heart failure; Systolic dysfunction; Positron emission tomography; Obesity; Fatty acids; Glucose; IDIOPATHIC DILATED CARDIOMYOPATHY; FATTY-ACID-METABOLISM; LEFT-VENTRICULAR FUNCTION; POSITRON-EMISSION-TOMOGRAPHY; SUBSTRATE METABOLISM; INSULIN-RESISTANCE; DOUBLE-BLIND; CARBOHYDRATE-METABOLISM; GLUCOSE-METABOLISM; DIABETES-MELLITUS;
D O I
10.1007/s10741-012-9360-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myocardial substrate metabolism provides the energy needed for cardiac contraction and relaxation. The normal adult heart uses predominantly fatty acids (FAs) as its primary fuel source. However, the heart can switch and use glucose (and to a lesser extent, ketones, lactate, as well as endogenous triglycerides and glycogen), depending on the metabolic milieu and superimposed conditions. FAs are not a wholly better fuel than glucose, but they do provide more energy per mole than glucose. Conversely, glucose is the more oxygen-efficient fuel. Studies in animal models of heart failure (HF) fairly consistently demonstrate a shift away from myocardial fatty acid metabolism and toward glucose metabolism. Studies in humans are less consistent. Some show the same metabolic switch away from FA metabolism but not all. This may be due to differences in the etiology of HF, sex-related differences, or other mitigating factors. For example, obesity, insulin resistance, and diabetes are all related to an increased risk of HF and may complicate or contribute to its development. However, these conditions are associated with increased FA metabolism. This review will discuss aspects of human heart metabolism in systolic dysfunction as measured by the noninvasive, quantitative method-positron emission tomography. Continued research in this area is vital if we are to ameliorate HF by manipulating heart metabolism with the aim of increasing energy production and/or efficiency.
引用
收藏
页码:567 / 574
页数:8
相关论文
共 52 条
[41]  
Shah Ankur, 2003, Rev Cardiovasc Med, V4 Suppl 6, pS50
[42]   Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions - Potential for pharmacological interventions [J].
Stanley, WC ;
Lopaschuk, GD ;
Hall, JL ;
McCormack, JG .
CARDIOVASCULAR RESEARCH, 1997, 33 (02) :243-257
[43]  
Taylor M, 2001, J NUCL MED, V42, P55
[44]   Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy [J].
Tuunanen, Helena ;
Engblom, Erik ;
Naum, Alexandru ;
Nagren, Kjell ;
Scheinin, Mika ;
Hesse, Birger ;
Airaksinen, K. E. Juhani ;
Nuutila, Pirjo ;
Iozzo, Patricia ;
Ukkonen, Heikki ;
Opie, Lionel H. ;
Knuuti, Juhani .
CIRCULATION, 2008, 118 (12) :1250-1258
[45]   Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure [J].
Tuunanen, Helena ;
Engblom, Erik ;
Naum, Alexandru ;
Nagren, Kjell ;
Hesse, Birger ;
Airaksinen, Juhani ;
Nuutila, Pirjo ;
Iozzo, Patricia ;
Ukkonen, Heikki ;
Opie, Lionel H. ;
Knuuti, Juhani .
CIRCULATION, 2006, 114 (20) :2130-2137
[46]   Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy:: Evidence of relationship with insulin resistance and left ventricular dysfunction [J].
Tuunanen, Helena ;
Engblom, Erik ;
Naum, Alexandru ;
Scheinin, Mika ;
Nagren, Kjell ;
Airaksinen, Juhani ;
Nuutila, Pirjo ;
Iozzo, Patricia ;
Ukkonen, Heikki ;
Knuuti, Juhani .
JOURNAL OF CARDIAC FAILURE, 2006, 12 (08) :644-652
[47]   Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease [J].
Vitale, C ;
Wajngaten, M ;
Sposato, B ;
Gebara, O ;
Rossini, P ;
Fini, M ;
Volterrani, M ;
Rosano, GMC .
EUROPEAN HEART JOURNAL, 2004, 25 (20) :1814-1821
[48]  
Wallhaus TR, 2001, CIRCULATION, V103, P2441
[49]   DEFECTIVE LIPID METABOLISM IN FAILING HEART [J].
WITTELS, B ;
SPANN, JF .
JOURNAL OF CLINICAL INVESTIGATION, 1968, 47 (08) :1787-&
[50]   Angiotensin-converting enzyme inhibition improves cardiac fatty acid metabolism in patients with congestive heart failure [J].
Yamauchi, S ;
Takeishi, Y ;
Minamihaba, O ;
Arimoto, T ;
Hirono, O ;
Takahashi, H ;
Miyamoto, T ;
Nitobe, J ;
Nozaki, N ;
Tachibana, H ;
Watanabe, T ;
Fukui, A ;
Kubota, I .
NUCLEAR MEDICINE COMMUNICATIONS, 2003, 24 (08) :901-906